The Roundup – August 3, 2023

• BioCT welcomes The Jackson Laboratory as new member, appoints Charles Lee to the board of directors

Member News

• Arvinas and Pfizer awarded Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant
• Cellinfinity Bio announces publication and licensing of key technology for directed evolution of cells that allows for more effective adoptive cell therapy
• Unlocking clinical data with Jackson Labs
• Regenerative Agriculture 101 with Enko Chem: A healthy environment is built from the ground up
• UConn researcher identifies key mechanism in Parkinson’s disease research

More Industry News

• New Haven featured in CondeNaste Traveler
• NIH taps infectious disease doctor Jeanne Marrazzo to succeed Fauci as NIAID head

Curie.Bio is a new model for venture capital in biotech focused on helping founders launch serious biotech therapeutics companies. Founded by Alexis Borisy, Christoph Lengauer and Zach Weinberg, Curie.Bio is a unique combination of two businesses: they act as both your drug discovery co-pilot & seed investor. They have some of the world’s best drug hunters, drug makers, experts, and vendors supporting founders to increase their chances of developing successful medicines. They help founders avoid mistakes and ensure they have the right data, plan, and story to retain ownership and control over their own company. By doing this, Curie.Bio is enabling more founders with phenomenal ideas to have the support they need to start their own companies. Check out our recent press coverage from STAT, Fast Company, and BIOS.If members of BioCT are interested in learning more about Curie.Bio and the founder-friendly platform they are building, please reach out directly to Clinton Bourbonais at clinton@curie.bio. If your company is looking for funding and is a pre-Series A therapeutics company, please send materials (pitch deck, papers, 1-page summaries, etc.) to Clinton or submit your company for review on the website here. 

A Golden Ticket, including a fully paid individual bench and membership to a US Biolabs site (i.e. New Haven), is now available! Startups working on R&D in gene editing, mRNA or siRNA, and/or relevant viral and non-viral delivery technologies for treating rare hematology, immunology, ophthalmology, dermatology, metabolic or lysosomal storage diseases should consider applying. Sponsored by Chiesi

The application deadline is September 22nd so apply now!

Accelerated Leadership
August 29 – September 19, 2023 (12:30 PM)
Biotechnology Project Management **
September 11 – October 6, 2023 (5:00 PM)
Intro to Biotech**
September 14 – 15, 2023 (10:00 AM – 5:00 PM)
Supply Chain Management
September 18 – 25, 2023 (10:00 AM – 12:30 PM)
Finance of Biotech**
September 19, 2023 (9:00 AM – 5:00 PM)

**All or some classes will be held in-person at MassBioEd Office (Cambridge, MA)